AMANDA DAVIS: Open Payments
NPI 1790220143 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,191 in 41 payments from 9 companies in 2025. Trend: 2023 $18,270 · 2024 $18,974 · 2025 $5,191
Consulting: $1,840Travel & lodging: $1,396Speaker / faculty: $1,130Food & beverage: $826
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 18 | $4,706 |
| Ipsen Biopharmaceuticals, Inc | 13 | $217 |
| Regeneron Healthcare Solutions, Inc. | 2 | $76 |
| Madrigal Pharmaceuticals | 2 | $58 |
| ABBVIE INC. | 2 | $55 |
| Janssen Biotech, Inc. | 1 | $25 |
| ORPHALAN INC | 1 | $19 |
| Novo Nordisk Inc | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
Products named: Epclusa, IQIRVO, DUPIXENT, REZDIFFRA, MAVYRET, TREMFYA, CUVRIOR, Bylvay.
Industry payments across AR — which companies pay providers there.
